menu
    • menu
    [{"orgOrder":0,"company":"Eyestem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Rare Diseases and Disorders","country":"INDIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Eyecyte-RPE","moa":"Undisclosed","graph1":"Rare Diseases and Disorders","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Rare Diseases","amount2New":0,"dosageForm":"Suspension","sponsorNew":"Eyestem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Undisclosed"},{"orgOrder":0,"company":"Eyestem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell & Gene Therapy","year":"2025","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Injection","sponsorNew":"Eyestem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Undisclosed"},{"orgOrder":0,"company":"Eyestem","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell & Gene Therapy","year":"2024","type":"Inapplicable","leadProduct":"Pluripotent Stem Cell","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"IND Enabling","graph3":"Eyestem","amount2":0,"highestDevelopmentShortName":"IND","therapeuticAreaShortName":"Ophthalmology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Eyestem \/ Undisclosed","highestDevelopmentStatusID":"5","companyTruncated":"Eyestem \/ Undisclosed"},{"orgOrder":0,"company":"Eyestem","sponsor":"Undisclosed","pharmaFlowCategory":"D","therapeuticArea":"Ophthalmology","country":"INDIA","productType":"Cell & Gene Therapy","year":"2025","type":"Financing","leadProduct":"Eyecyte-RPE","moa":"Undisclosed","graph1":"Ophthalmology","graph2":"Phase I\/ Phase II","graph3":"Eyestem","amount2":0.01,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Ophthalmology","amount2New":0.01,"dosageForm":"Injection","sponsorNew":"Eyestem \/ Undisclosed","highestDevelopmentStatusID":"7","companyTruncated":"Eyestem \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Eyestem

    Menu

    Eyestem

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pluripotent Stem Cell,Eyecyte-RPE

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            DEALS_DEV arrow-down

                            Eyestem Research Raises $10 Million to Advance Eyecyte-RPE Cell Therapy for Dry AMD

                            Details : The proceeds will be used to support the next stage of development for its investigational retinal pigment epithelial cell therapy, Eyecyte-RPE being developed for patients with geographic atrophy.

                            Product Name : Eyecyte-RPE

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Undisclosed

                            August 11, 2025

                            Lead Product(s) : Pluripotent Stem Cell,Eyecyte-RPE

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : $10.0 million

                            Deal Type : Financing

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Pluripotent Stem Cell

                            Therapeutic Area : Ophthalmology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eyestem's Eyecyte-RPE Trial Shows Vision Rescue for Geographic Atrophy Patients

                            Details : Eyecyte-RPE is an allogeneic RPE cell suspension which replaces damaged retinal cells and restores vision. It is being investigated in geographic atrophy secondary to dry AMD.

                            Product Name : Eyecyte-RPE

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 15, 2025

                            Lead Product(s) : Pluripotent Stem Cell

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Eyecyte-RPE

                            Therapeutic Area : Rare Diseases and Disorders

                            Study Phase : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Safety & Efficacy of Eyecyte-RPEâ„¢ in Patients With Geographic Atrophy Secondary to Dry Age-related Macul...

                            Details : Eyecyte-RPE is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Retinal Diseases.

                            Product Name : Undisclosed

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            May 01, 2024

                            Lead Product(s) : Eyecyte-RPE

                            Therapeutic Area : Rare Diseases and Disorders

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed

                            Eyestem

                            India arrow
                            Global ChemShow
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Retinal Pigment Epithelium Cell,Pluripotent Stem Cell

                            Therapeutic Area : Ophthalmology

                            Study Phase : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Eyestem to Begin Human Trials for its Pioneering Dry AMD Treatment

                            Details : Eyecyte RPE, is a lost or damaged retinal pigment epithelium cells replacement therapy is being investigated for the treatment geographic atrophy arising from dry age-related macular degeneration

                            Product Name : Eyecyte-RPE

                            Product Type : Cell & Gene Therapy

                            Upfront Cash : Inapplicable

                            April 02, 2024

                            Lead Product(s) : Retinal Pigment Epithelium Cell,Pluripotent Stem Cell

                            Therapeutic Area : Ophthalmology

                            Highest Development Status : IND Enabling

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth